World & BusinessNovo's turnaround effort amid Eli Lilly's gains in GLP-1s
Some analysts say Lilly has advantages that could help it stay at the top of the obesity drug market, CNBC reports.
TLDR
CNBC reports that Novo is betting on its next chapter as Eli Lilly gains ground in GLP-1s. As Novo works to turn itself around, some analysts cited by CNBC say Lilly's advantages could help it maintain its lead in the obesity drug market.
Novo's turnaround effort amid Eli Lilly's gains in GLP-1s
Some analysts say Lilly has advantages that could help it stay at the top of the obesity drug market, CNBC reports.
TLDR
CNBC reports that Novo is betting on its next chapter as Eli Lilly gains ground in GLP-1s. As Novo works to turn itself around, some analysts cited by CNBC say Lilly's advantages could help it maintain its lead in the obesity drug market.